

MEDICAL POLICY

POLICY TITLE	VISION THERAPY
POLICY NUMBER	MP 4.007

CLINICAL BENEFIT	☐ MINIMIZE SAFETY RISK OR CONCERN. ☒ MINIMIZE HARMFUL OR INEFFECTIVE INTERVENTIONS. ☐ ASSURE APPROPRIATE LEVEL OF CARE. ☐ ASSURE APPROPRIATE DURATION OF SERVICE FOR INTERVENTIONS. ☒ ASSURE THAT RECOMMENDED MEDICAL PREREQUISITES HAVE BEEN MET. ☐ ASSURE APPROPRIATE SITE OF TREATMENT OR SERVICE.
Effective date:	10/1/2026

POLICY

Vision therapy may be considered **medically necessary** for symptomatic convergence insufficiency. Some examples (not all-inclusive) of conditions that can cause convergence insufficiency are the following conditions:

- Amblyopia
- Strabismus
- Accommodative dysfunction
- General binocular dysfunction
- Mild traumatic brain injury (mTBI)
- Concussion
- Stroke

More than 24 sessions of vision therapy are considered **investigational** per symptomatic occurrence (see policy guidelines).

Vision therapy is considered **investigational** for all other indications. There is insufficient evidence to support a conclusion concerning the health outcomes or benefits associated with this procedure.

Orthoptic eye exercises are considered **investigational** for the treatment of learning disabilities in the absence of symptomatic convergence insufficiency.

A home computer orthoptic program consisting of eye exercises performed when following computer instructions that is tailored to the individual's personal binocular problem is considered **investigational**. There is insufficient evidence to support a conclusion concerning the health outcomes or benefits associated with this procedure for these indications.

Policy Guidelines

This policy addresses office-based orthoptic training. This policy does not address standard vision therapy with lenses, prisms, filters or occlusion (i.e., for treatment of amblyopia or acquired esotropia prior to surgical intervention).

Up to 12 sessions of office-based vision therapy, typically performed once per week, has been shown to improve symptomatic convergence insufficiency. If individuals remain symptomatic

MEDICAL POLICY

POLICY TITLE	VISION THERAPY
POLICY NUMBER	MP 4.007

after 12 weeks of orthoptic training, yet there is documentation of improvement through examination notes, then another 12 sessions may be needed.

The American Association for Pediatric Ophthalmology and Strabismus states on their website:

At times, convergence insufficiency symptoms will resurface after illness, lack of sleep or increased near work demands. If treatment had been successful previously, an additional course of treatment may be successful at resolving recurrent symptoms.

A diagnosis of convergence insufficiency is based on asthenopic symptoms (sensations of visual or ocular discomfort) at near point combined with difficulty sustaining convergence.

Convergence insufficiency and stereoacuity are documented by:

- Exodeviation at near vision at least 4 prism diopters greater than at far; AND
- Insufficient positive fusional vergence at near (positive fusional vergence (PFV) less than 15 prism diopters blur or break) on PFV testing using a prism bar; AND
- Near point of convergence (NPC) break of more than 6 cm; AND
- Appreciation by the patient of at least 500 seconds of arc on stereoacuity testing.

Cross-references:

MP 2.304 Medical Treatments of Autism Spectrum Disorders

MP 6.058 Intraocular Lenses, Spectacle Correction, and Iris Prosthesis

PRODUCT VARIATIONS

This policy is only applicable to certain programs and products administered by Capital Blue Cross and subject to benefit variations. Please see additional information below.

FEP PPO: Refer to FEP Medical Policy Manual. The FEP Medical Policy manual can be found at:

<https://www.fepblue.org/benefit-plans/medical-policies-and-utilization-management-guidelines/medical-policies>

DESCRIPTION/BACKGROUND

Common forms of vision therapy are known as orthoptics and pleoptics. Orthoptics is a technique of eye exercises intended to improve eye movements and/or visual tracking. Pleoptics are eye exercises used to improve impaired vision when there is no evidence of organic eye diseases. A related but distinct training technique is behavioral or perceptual vision therapy, in which eye movement and eye hand coordination training techniques are used to improve learning efficiency by optimizing visual processing skills.

The American Association for Pediatric Ophthalmology and Strabismus (AAPOS) states that optometrists define vision therapy as an attempt to develop or improve visual skills and abilities; improve visual comfort, ease, and efficiency; and change visual processing or interpretation of visual information. The AAPOS states that there are three main categories of vision therapy which are orthoptic vision therapy, behavioral/perceptual vision therapy, and vision therapy for

MEDICAL POLICY

POLICY TITLE	VISION THERAPY
POLICY NUMBER	MP 4.007

prevention or correction of myopia (nearsightedness). Orthoptic vision therapy includes eye exercises to improve binocular function whereas behavioral/perceptual vision therapy includes eye exercises to improve visual processing and visual perception. Orthoptic eye exercises can be beneficial in the treatment of symptomatic convergence insufficiency.

Convergence insufficiency (CI) is a binocular vision disorder in the ability for the eyes to turn inward towards each other (e.g., when looking at near objects). It is most common in children and young adults when they begin to experience symptoms from prolonged periods of near work. Symptoms of this condition may include eyestrain, headaches, blurred vision, diplopia, sleepiness, difficulty concentrating, movement of print, and loss of comprehension after short periods of reading or performing close activities. Prism reading glasses, home therapy with pencil push-ups, and office-based vision therapy and orthoptics have been evaluated for the treatment of convergence insufficiency. Prism reading glasses tend to treat the symptom of double vision but does not actually treat the condition itself. The goal of vision therapy in the treatment of CI is to stimulate the communication between the brain and eyes, to enable clear and comfortable vision at all times.

In addition to its use in the treatment of accommodative and convergence dysfunction, vision therapy is being investigated for the treatment of attention deficient disorders, dyslexia, dysphasia, and reading disorders. The American Academy of Ophthalmology, in a joint statement on learning disabilities, dyslexia, and vision, concluded that:

Currently, there is no adequate scientific evidence to support the view that subtle eye or visual problems cause learning disabilities. Furthermore, the evidence does not support the concept that vision therapy or tinted lenses or filters are effective, directly or indirectly, in the treatment of learning disabilities. Thus, the claim that vision therapy improves visual efficiency cannot be substantiated. Diagnostic and treatment approaches that lack scientific evidence of efficacy are not endorsed or recommended.

Computer based programs

RevitalVision received FDA clearance for its vision training software program which provides home-based vision training to people 9 years of age and older with amblyopia.

The CureSight system is a non-invasive eye tracking system designed for remote binocular vision treatment in pediatric patients (aged 4 to 9 years) suffering from amblyopia. The proprietary screen allows for treatment while the child watches their favorite streamed content in the comfort of their home.

RATIONALE

Summary of Evidence

For individuals who have convergence insufficiency who receive office-based orthoptic training, the evidence includes a TEC Assessment, several randomized controlled trials (RCTs), and nonrandomized comparative studies. Relevant outcomes are symptoms and functional outcomes. The most direct evidence on office-based orthoptic training comes from a 2008 RCT that demonstrated office-based vision or orthoptic training improves symptoms of convergence

MEDICAL POLICY

POLICY TITLE	VISION THERAPY
POLICY NUMBER	MP 4.007

insufficiency in a greater percentage of patients than a home-based vision exercise program consisting of pencil push-ups or home computer vision exercises. Subgroup analyses of this RCT demonstrated improvements in accommodative vision, parental perception of academic behavior, and specific convergence insufficiency symptoms. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have learning disabilities who receive office-based orthoptic training, the evidence includes a TEC Assessment as well as nonrandomized comparative and noncomparative studies. Relevant outcomes are functional outcomes. A 1996 TEC Assessment did not find evidence that orthoptic training improves outcomes for individuals with learning disabilities. Since that publication, peer-reviewed studies have not directly demonstrated improvements in reading or learning outcomes with orthoptic training. At least 2 earlier studies that have addressed other types of vision therapies reported mixed improvements in reading. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have received computer-based therapy programs, the evidence includes a prospective study to evaluate the efficacy of perceptual vision therapy in enhancing best corrected visual acuity and contrast sensitivity function in amblyopic patients. The authors concluded the results demonstrate the efficacy of perceptual vision therapy in improving visual acuity. Long-term follow-up and further studies are needed. The evidence is insufficient to determine the effects of the technology on health outcomes.

DEFINITIONS

ACCOMMODATION is the adjustment of the optics of the eye to keep an object in focus on the retina as its distance from the eye varies.

AMBLYOPIA is reduced vision, typically in one eye, that results from the brain suppressing input from the affected eye due to unequal visual signals from each eye leading to poor development of visual acuity in the affected eye.

BINOCULAR VISION is the visual sensation that is produced when the images perceived by each eye are fused to appear as one.

STRABISMUS refers to an abnormal ocular condition in which the visual axes of the eyes are not directed at the same point.

DISCLAIMER

Capital Blue Cross' medical policies are used to determine coverage for specific medical technologies, procedures, equipment, and services. These medical policies do not constitute medical advice and are subject to change as permitted by law or applicable clinical evidence from independent treatment guidelines. Treating providers are solely responsible for medical advice and treatment of members. These policies are not a guarantee of coverage or payment. Payment of claims is subject to a determination regarding the member's benefit program and eligibility on the date of service, and a determination that the services are medically necessary and appropriate. Final processing of a claim is based upon the terms of contract that applies to

MEDICAL POLICY

POLICY TITLE	VISION THERAPY
POLICY NUMBER	MP 4.007

the members' benefit program, including benefit limitations and exclusions. If a provider or a member has a question concerning this medical policy, please contact Capital Blue Cross' Provider Services or Member Services.

CODING INFORMATION

Note: This list of codes may not be all-inclusive, and codes are subject to change at any time. The identification of a code in this section does not denote coverage as coverage is determined by the terms of member benefit information. In addition, not all covered services are eligible for separate reimbursement.

Investigational, therefore not covered:

Procedure Codes							
0687T	0688T	0704T	0705T	0706T	A9292		

Covered when medically necessary:

Procedure Codes							
92065	92066						

ICD-10-CM Diagnosis Codes	Description
H51.11	Convergence insufficiency
H51.12	Convergence excess

REFERENCES

1. Handler SM, Fierson WM, American Academy of Ophthalmology Section on Ophthalmology and Council on Children with Disabilities, et al. Learning disabilities, dyslexia, and vision. *Pediatrics*. Mar 2011;127(3):e818-856. PMID 21357342
2. Rawstron JA, Burley CD, Elder MJ. A systematic review of the applicability and efficacy of eye exercises. *J Pediatr Ophthalmol Strabismus*. Mar-Apr 2005;42(2):82-88. PMID 15825744
3. Scheiman M, Gwiazda J, Li T. Non-surgical interventions for convergence insufficiency. *Cochrane Database Syst Rev*. Mar 16 2011(3):CD006768. PMID 21412896
4. Convergence Insufficiency Treatment Trial Study Group. Randomized clinical trial of treatments for symptomatic convergence insufficiency in children. *Arch Ophthalmol*. Oct 2008;126(10):1336-1349. PMID 18852411

MEDICAL POLICY

POLICY TITLE	VISION THERAPY
POLICY NUMBER	MP 4.007

5. *Convergence Insufficiency Treatment Trial Study Group. Long-term effectiveness of treatments for symptomatic convergence insufficiency in children. Optom Vis Sci. Sep 2009;86(9):1096-1103. PMID 19668097*
6. *Scheiman M, Cotter S, Kulp MT, et al. Treatment of accommodative dysfunction in children: results from a randomized clinical trial. Optom Vis Sci. Nov 2011;88(11):1343-1352. PMID 21873922*
7. *Borsting E, Mitchell GL, Kulp MT, et al. Improvement in academic behaviors after successful treatment of convergence insufficiency. Optom Vis Sci. Jan 2012;89(1):12-18. PMID 22080400*
8. *Barnhardt C, Cotter SA, Mitchell GL, et al. Symptoms in children with convergence insufficiency: before and after treatment. Optom Vis Sci. Oct 2012;89(10):1512-1520. PMID 22922781*
9. *Scheiman M, Cotter S, Rouse M, et al. Randomised clinical trial of the effectiveness of base-in prism reading glasses versus placebo reading glasses for symptomatic convergence insufficiency in children. Br J Ophthalmol. Oct 2005;89(10):1318-1323. PMID 16170124*
10. *Scheiman M, Mitchell GL, Cotter S, et al. A randomized clinical trial of treatments for convergence insufficiency in children. Arch Ophthalmol. Jan 2005;123(1):14-24. PMID 15642806*
11. *Shin HS, Park SC, Maples WC. Effectiveness of vision therapy for convergence dysfunctions and long-term stability after vision therapy. Ophthalmic Physiol Opt. Mar 2011;31(2):180-189. PMID 21309805*
12. *Dusek WA, Pierscionek BK, McClelland JF. An evaluation of clinical treatment of convergence insufficiency for children with reading difficulties. BMC Ophthalmol. Aug 11 2011;11:21. PMID 21835034*
13. *Lee SH, Moon BY, Cho HG. Improvement of vergence movements by vision therapy decreases K-ARS scores of symptomatic adhd children. J Phys Ther Sci. Feb 2014;26(2):223-227. PMID 24648636*
14. *Momeni-Moghaddam H, Kundart J, Azimi A, et al. The effectiveness of home-based pencil push-up therapy versus office-based therapy for the treatment of symptomatic convergence insufficiency in young adults. Middle East Afr J Ophthalmol. Jan-Mar 2015;22(1):97-102. PMID 25624682*
15. *Borsting E, Mitchell GL, Arnold LE, et al. Behavioral and emotional problems associated with convergence insufficiency in children: an open trial. J Atten Disord. Oct 2016;20(10):836-844. PMID 24271946*
16. *Ramsay MW, Davidson C, Ljungblad M, et al. Can vergence training improve reading in dyslexics? Strabismus. Dec 2014;22(4):147-151. PMID 25333204*
17. *Stein JF, Richardson AJ, Fowler MS. Monocular occlusion can improve binocular control and reading in dyslexics. Brain. Jan 2000;123(Pt 1):164-170. PMID 10611130*
18. *Christenson GN, Griffin JR, Taylor M. Failure of blue-tinted lenses to change reading scores of dyslexic individuals. Optometry. Oct 2001;72(10):627-633. PMID 11712629*
19. *Grisham D, Powers M, Riles P. Visual skills of poor readers in high school. Optometry. Oct 2007;78(10):542-549. PMID 17904495*

MEDICAL POLICY

POLICY TITLE	VISION THERAPY
POLICY NUMBER	MP 4.007

20. *Palomo-Alvarez C, Puell MC. Accommodative function in school children with reading difficulties. Graefes Arch Clin Exp Ophthalmol. Dec 2008;246(12):1769-1774. PMID 18751994*
21. *Ponsonby AL, Williamson E, Smith K, et al. Children with low literacy and poor stereoacuity: an evaluation of complex interventions in a community-based randomized trial. Ophthalmic Epidemiol. Sep-Oct 2009;16(5):311- 321. PMID 19874111*
22. *Joint statement: learning disabilities, dyslexia, and vision reaffirmed 2014. American Academy of Ophthalmology, American Association for Pediatric Ophthalmology and Strabismus, American Association of Certified Orthoptists, et al. Updated July 2014.*
23. *Yalcin E, Balci O. Efficacy of perceptual vision therapy in enhancing visual acuity and contrast sensitivity function in adult hypermetropic anisometropic amblyopia. Clin Ophthalmol. 2014;8:49-53. doi:10.2147/OPTH.S48300*
24. *Searle A, Rowe FJ. Vergence Neural Pathways: A Systematic Narrative Literature Review. Neuroophthalmology. 2016;40(5):209-218. Published 2016 Sep 2. doi:10.1080/01658107.2016.1217028*
25. *Merezhinskaya N, Mallia RK, Park D, Bryden DW, Mathur K, Barker FM 2nd. Visual Deficits and Dysfunctions Associated with Traumatic Brain Injury: A Systematic Review and Meta-analysis. Optom Vis Sci. 2019;96(8):542-555. doi:10.1097/OPX.0000000000001407*
26. *Coats DK, Paysse EA. Causes of horizontal strabismus in children. In: UpToDate Online Journal [serial online]. Waltham, MA: UpToDate; Updated March 26, 2021. Literature review current through August 2022.*
27. *Alvarez TL, Scheiman M, Santos EM, Yaramothu C, d'Antonio-Bertagnolli JV. Convergence Insufficiency Neuro-mechanism in Adult Population Study Randomized Clinical Trial: Clinical Outcome Results. Optom Vis Sci. 2020;97(12):1061-1069. doi:10.1097/OPX.0000000000001606*
28. *Chang MY, Morrison DG, Binenbaum G, et al. Home- and Office-Based Vergence and Accommodative Therapies for Treatment of Convergence Insufficiency in Children and Young Adults: A Report by the American Academy of Ophthalmology. Ophthalmology. 2021;128(12):1756-1765. doi:10.1016/j.ophtha.2021.05.017*
29. *Scheiman M, Kulp MT, Cotter SA, Lawrenson JG, Wang L, Li T. Interventions for convergence insufficiency: a network meta-analysis. Cochrane Database Syst Rev. 2020;12(12):CD006768. Published 2020 Dec 2. doi:10.1002/14651858.CD006768.pub3*
30. *Ghadban R, Martinez JM, Diehl NN, Mohny BG. The incidence and clinical characteristics of adult-onset convergence insufficiency. Ophthalmology. 2015 May;122(5):1056-9. doi: 10.1016/j.ophtha.2014.12.010. Epub 2015 Jan 24. PMID: 25626756; PMCID: PMC4414695.*
31. *American Association for Pediatric Ophthalmology and Strabismus. Glossary Entry titled Vision Therapy. Updated April 2023.*
32. *American Association for Pediatric Ophthalmology and Strabismus. Glossary Entry titled Convergence Insufficiency. Updated March 2023.*
33. *Lazarus R. Convergence Insufficiency. Optometrists Network. April 22, 2020.*

MEDICAL POLICY

POLICY TITLE	VISION THERAPY
POLICY NUMBER	MP 4.007

34. Fortenbaugh FC, Gustafson JA, Fonda JR, Fortier CB, Milberg WP, McGlinchey RE. Blast mild traumatic brain injury is associated with increased myopia and chronic convergence insufficiency. *Vision Res.* 2021;186:1-12. doi:10.1016/j.visres.2021.04.004
35. Chen AM, Roberts TL, Cotter SA, et al. Effectiveness of vergence/accommodative therapy for accommodative dysfunction in children with convergence insufficiency. *Ophthalmic Physiol Opt.* Jan 2021; 41(1): 21-32. PMID 33119180
36. Pina-Balofer A, Piñero DP, Buigues M, Cavaliere-Ballesta C, Viudes S, Bataille L. Evaluation of the Efficacy of Treatment for Convergence Insufficiency with a New Digital Mobile Platform: A Comparative Preliminary Study. *Vision.* 2026; 10(2):31. <https://doi.org/10.3390/vision10020031>
37. Scheiman M, Gwiazda J, Li T. Non-surgical interventions for convergence insufficiency. *Cochrane Database Syst Rev.* 2011;(3):CD006768. doi:10.1002/14651858.CD006768.pub2. PMID: 21412896.
38. Lakhan SE. Postmarket safety surveillance of FDA-cleared prescription digital therapeutics using the Manufacturer and User Facility Device Experience (MAUDE) database: a pharmacovigilance study. *Cureus.* 2025;17(6):e85343.

POLICY HISTORY

MP 4.007	12/01/2022 Administrative Update. Added new code 92066; effective 01/01/2023
	04/28/2023 Consensus Review. Updated policy guidelines and references.
	09/07/2023 Administrative Update. Added new code A9292 to NMN table. Effective date 10/01/2023.
	06/20/2024 Consensus Review. Updated cross-references and references. No changes to coding.
	03/19/2025 Consensus Review. Updated NMN statement to INV; no change to intent. No changes to coding.
	02/20/2026 Administrative Update. Updated language preceding coding table (NMN to INV). Effective date 04/01/2026.
	07/28/2026 Consensus Review. No change to policy statement. No coding changes. References reviewed and updated.

Health care benefit programs issued or administered by Capital Blue Cross and/or its subsidiaries, Capital Advantage Insurance Company®, Capital Advantage Assurance Company® and Keystone Health Plan® Central. Independent licensees of the Blue Cross BlueShield Association. Communications issued by Capital Blue Cross in its capacity as administrator of programs and provider relations for all companies.